Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial @entity2791 : Results From the Stenting and Aggressive Medical Management for Preventing Recurrent XXXX (SAMMPRIS) Trial.

@entity1 @entity64 @entity6249 @entity6 @entity2791 @entity1188 @entity453 @entity62 @entity413 @entity385
Importance: Intracranial @entity2791 ( @entity6249 ) may coexist. There are limited data on the frequency and risk factors for coexistent @entity6249 and the effect of @entity6249 on @entity64 recurrence in @entity1 receiving medical treatment for ICAS. Objective: To investigate the frequency and risk factors for @entity6249 and the effect of @entity6249 on @entity64 recurrence in @entity1 with ICAS. Design, Setting, and @entity1 : A post hoc analysis of the Stenting and Aggressive Medical Management for Preventing Recurrent @entity64 (SAMMPRIS) study, a prospective, multicenter clinical trial. Among 451 @entity1 , 313 (69.4%) had baseline brain magnetic resonance imaging scans read centrally for @entity6249 that was defined by any of the following: old @entity1188 , grade 2 to 3 on the Fazekas scale (for high-grade @entity62 ), or microbleeds. @entity1 enrollment in SAMMPRIS began November 25, 2008, and follow-up ended on April 30, 2013. Data analysis for the present study was performed from May 13, 2014, to July 29, 2015. Main Outcomes and Measures: Risk factors in @entity1 with vs without @entity6249 and the association between @entity6249 and other baseline risk factors with any @entity385 and @entity385 in the territory of the stenotic artery determined using proportional hazards regression. Results: Of 313 @entity1 , 155 individuals (49.5%) had @entity6249 noted on baseline magnetic resonance imaging. Variables that were significantly higher in @entity1 with @entity6249 , reported as mean (SD), included age, 63.5 (10.5) years (P   <   .001), systolic blood pressure, 149 (22) mm Hg (P   <   .001), @entity413 level, 130 (50) mg/dL (P   =   .03), and lower Montreal Cognitive Assessment scores (median, >= 24 [interquartile range, 20-26]; P   =   .02).Other significant variables were the number of @entity1 with @entity6 (88 of 155 [56.8%]; P   =   .003), @entity453 (46 [29.7%]; P   =   .004), @entity64 before the qualifying event (59 [38.1%]; P   <   .001), old @entity1188 in the territory of the stenotic intracranial artery (88 [56.8%]; P   <   .001), and receiving antithrombotic therapy at the time of the qualifying event (109 [70.3%]; P   =   .005). The association between @entity6249 and any @entity385 was nearly significant in the direction of a higher risk (18 [23.7%]); P   =   .07) for @entity1 with @entity6249 . On bivariate analysis, @entity6249 was not associated with an increased risk on multivariable analyses (hazard ratio, 1.7 [95% CI, 0.8-3.8]; P   =   .20). In addition, @entity6249 was not associated with an increased risk of @entity64 in the territory on either bivariate or multivariable analyses. Conclusions and Relevance: Although @entity6249 is common in @entity1 with ICAS, the presence of @entity6249 on baseline magnetic resonance imaging is not independently associated with an increased risk of @entity64 in @entity1 with ICAS. Trial Registration: clinicaltrials.gov Identifier: NCT00576693.
